The observed changes in total and LDL cholesterol during semaglutide treatment in our cohort were in line with a systematic review and meta-analysis addressing the efficacy and safety of GLP-1 RAs on body weight and cardiometabolic parameters in individuals with obesity and without diabetes and with a systematic review and meta-analysis of semaglutide 2.4 mg including the 2-year STEP 5 trial (40, 41). The gene discussed is GLP1R; the disease is diabetes mellitus.